MedPath

A study to measure the Peg-Asparaginase (a chemotherapy medicine) drug levels in the body and observe and record allergies after its use in children receiving treatment for acute lymphoblastic leukemia (a type of blood cancer).

Not Applicable
Conditions
Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Registration Number
CTRI/2024/03/063700
Lead Sponsor
Dr Chetan Dhamne
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Children less than equal to 15 years of age with B-ALL or T-ALL receiving PEG asparaginaseas per ICICLE 2014 or standard of care treatment protocol at TMH.

Exclusion Criteria

1. Children who have received Asparginase as cytoreductive therapy for hyperleukocytosis will not be eligible for this study.

2. Children who receive native L asparaginase will not be eligible for the study.

3. Children who default treatment during induction of undergo induction death will be taken off study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Incidence of Grade I to II hypersensitivity reactions due to PEG asparaginase. <br/ ><br>2. Incidence of Grade III and IV hypersensitivity reactions due to PEG asparaginase. <br/ ><br>3. Incidence of neutralizing antibodies to PEG asparaginasein the presence ofhypersensitivity reactions and silent inactivation.Timepoint: Measure the anti-asparaginase antibodies on day 14 after the PEG asparaginase administration. <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1. Volume of distribution, clearance, AUC, the half-life of PEG asparaginase in pediatric ALL patients. <br/ ><br>Timepoint: First sample will be collected at 48 hours after the PEG asparaginase injection, <br/ ><br>Second sample between 4th to 5th day, one sample between 6th to 8th day, one sample on day 14 (trough level) and 1 day after the PEG asparaginase administration.
© Copyright 2025. All Rights Reserved by MedPath